GGrantIndex
← Leaderboards

Carl E Allen

Baylor College Of Medicine

Google Scholar ↗PubMed ↗ORCID ↗
$9,873,324
Attributed
$21,176,628
Total exposure
9
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $9.5M · FY2011–25
$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$26,850,114 · 10

By mechanism

R01$9,363,083 · 3
U54$6,584,506 · 3
R33$6,271,251 · 1
K12$3,005,298 · 1
R61$1,595,976 · 1
R13$30,000 · 1

Top collaborators

Most similar at Baylor College Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Child”

Research focus

ChildPathway InteractionsProgramsDesignDiagnosisChildhoodResponseMalignant NeoplasmsTexasPediatric HospitalsMedicineCollegeLesionLangerhans CellMalignant Childhood NeoplasmBaseClinical ResearchIncidencePediatric Oncology GroupImproved OutcomeBraf GeneDendritic CellsLaboratoriesEosinophilic Granuloma

Grant awards (41)

PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAM$810,000
K12 · FY2025 · CA · contact PI
Defining Pathogenic Mechanisms and Therapeutic Opportunities for Langerhans Cell Histiocytosis$646,985
R01 · FY2025 · CA
Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for sub-Saharan Africa (PARCA)$1,049,277
U54 · FY2024 · CA · contact PI
PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAM$732,227
K12 · FY2024 · CA · contact PI
Defining Pathogenic Mechanisms and Therapeutic Opportunities for Langerhans Cell Histiocytosis$618,128
R01 · FY2024 · CA
Establishing a Platform for Clinical Improvement for Children with HIV-Associated Malignancies in Sub-Saharan Africa$219,459
U54 · FY2024 · CA · contact PI
Administrative Core$76,315
U54 · FY2024 · CA · contact PI
Defining Clinical Research Priorities and Strengthening Diversity and Patient-Stakeholder Engagement in Histiocytic Disorders$30,000
R13 · FY2024 · TR
The PreVAIL-kIds Common Protocol$3,148,282
R33 · FY2023 · HD
AICORE-kids: Artificial Intelligence COVID-19 Risk AssEssment for kids$1,565,899
R33 · FY2023 · HD
AICORE-kids: Artificial Intelligence COVID-19 Risk AssEssment for kids$1,557,070
R33 · FY2023 · HD
Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for sub-Saharan Africa (PARCA)$1,106,039
U54 · FY2023 · CA
PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAM$717,393
K12 · FY2023 · CA
Defining Pathogenic Mechanisms and Therapeutic Opportunities for Langerhans Cell Histiocytosis$654,245
R01 · FY2023 · CA
Molecular Epidemiology of Langerhans Cell Histiocytosis: Evaluating the Impact of SMAD6 and Genetic Ancestry on Disease Risk$586,780
R01 · FY2023 · CA
Establishing a Platform for Clinical Improvement for Children with HIV-Associated Malignancies in Sub-Saharan Africa$147,944
U54 · FY2023 · CA · contact PI
Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for sub-Saharan Africa (PARCA)$1,103,769
U54 · FY2022 · CA
AICORE-kids: Artificial Intelligence COVID-19 Risk AssEssment for kids$778,430
R61 · FY2022 · HD
PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAM$745,678
K12 · FY2022 · CA
Defining Pathogenic Mechanisms and Therapeutic Opportunities for Langerhans Cell Histiocytosis$674,948
R01 · FY2022 · CA
Molecular Epidemiology of Langerhans Cell Histiocytosis: Evaluating the Impact of SMAD6 and Genetic Ancestry on Disease Risk$590,439
R01 · FY2022 · CA
Establishing a Platform for Clinical Improvement for Children with HIV-Associated Malignancies in Sub-Saharan Africa$149,749
U54 · FY2022 · CA · contact PI
Mentored Clinical Research to Improve Outcomes for Pediatric Mature B Cell Lymphoma in Uganda$125,000
U54 · FY2022 · CA
Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for sub-Saharan Africa (PARCA)$1,104,325
U54 · FY2021 · CA
AICORE-kids: Artificial Intelligence COVID-19 Risk AssEssment for kids$817,546
R61 · FY2021 · HD
Molecular Epidemiology of Langerhans Cell Histiocytosis: Evaluating the Impact of SMAD6 and Genetic Ancestry on Disease Risk$626,300
R01 · FY2021 · CA
Establishing a Platform for Clinical Improvement for Children with HIV-Associated Malignancies in Sub-Saharan Africa$149,360
U54 · FY2021 · CA · contact PI
Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for sub-Saharan Africa (PARCA)$1,185,076
U54 · FY2020 · CA
Molecular Epidemiology of Langerhans Cell Histiocytosis: Evaluating the Impact of SMAD6 and Genetic Ancestry on Disease Risk$614,491
R01 · FY2020 · CA
ERK control of Dendritic Cell Differentiation, Homeostasis and Disease$399,583
R01 · FY2020 · CA
Establishing a Platform for Clinical Improvement for Children with HIV-Associated Malignancies in Sub-Saharan Africa$168,193
U54 · FY2020 · CA · contact PI
Molecular Epidemiology of Langerhans Cell Histiocytosis: Evaluating the Impact of SMAD6 and Genetic Ancestry on Disease Risk$665,852
R01 · FY2019 · CA
ERK control of Dendritic Cell Differentiation, Homeostasis and Disease$387,594
R01 · FY2019 · CA
ERK control of Dendritic Cell Differentiation, Homeostasis and Disease$439,083
R01 · FY2018 · CA
ERK control of Dendritic Cell Differentiation, Homeostasis and Disease$439,083
R01 · FY2017 · CA
ERK control of Dendritic Cell Differentiation, Homeostasis and Disease$416,958
R01 · FY2016 · CA
Redefining Langerhans Cell Histiocytosis as a Myeloid Dysplasia and Identifying B$326,398
R01 · FY2015 · CA · contact PI
Redefining Langerhans Cell Histiocytosis as a Myeloid Dysplasia and Identifying B$316,606
R01 · FY2014 · CA · contact PI
Redefining Langerhans Cell Histiocytosis as a Myeloid Dysplasia and Identifying B$306,814
R01 · FY2013 · CA · contact PI
Redefining Langerhans Cell Histiocytosis as a Myeloid Dysplasia and Identifying B$326,398
R01 · FY2012 · CA · contact PI
Redefining Langerhans Cell Histiocytosis as a Myeloid Dysplasia and Identifying B$326,398
R01 · FY2011 · CA · contact PI